There is no single best medication for type 2 diabetes. Metformin remains the recommended first-line treatment for most people, but the “best” choice depends heavily on your individual health profile, particularly whether you also have heart disease, kidney disease, or need to lose weight. Newer drug classes now offer benefits that go well beyond blood sugar control, which has reshaped how doctors approach treatment.
Why Metformin Is Still the Starting Point
Metformin, combined with lifestyle changes, is the first medication most people with type 2 diabetes will take. It works primarily in the liver, improving how your body responds to insulin so that less sugar gets released into your bloodstream. At a standard dose, it lowers A1c by about 1 percentage point over six months. In clinical trials, 60% of patients achieved at least that 1% reduction. For someone starting with an A1c of 8%, that alone can bring them close to the 7% target most guidelines recommend.
Metformin is inexpensive, available as a generic, well-studied over decades, and carries a low risk of causing dangerously low blood sugar. The most common complaints are digestive: nausea, diarrhea, and stomach discomfort, which often improve after a few weeks or with an extended-release version. The main limitation is kidney function. If your eGFR (a measure of how well your kidneys filter) drops below 30, metformin is off the table because of a small risk of a dangerous acid buildup in the blood. Between 30 and 45, doctors weigh the risks carefully and may reduce the dose.
GLP-1 Receptor Agonists: Strong Blood Sugar and Weight Effects
GLP-1 receptor agonists are injectable medications (some now available as daily pills) that mimic a gut hormone involved in insulin release. They signal your pancreas to produce more insulin when blood sugar is high, slow stomach emptying so you feel full longer, and reduce appetite. This class includes semaglutide (Ozempic, Rybelsus), liraglutide (Victoza), and dulaglutide (Trulicity).
In terms of raw blood sugar lowering, GLP-1 agonists are the most potent class available. Semaglutide at its higher dose lowers A1c by an estimated 1.77 percentage points in people new to medication, more than any other single drug on the market. Even at a lower dose, it achieves about 1.43 points. Dulaglutide manages roughly 1.2 to 1.4 points depending on dose, and liraglutide falls between 1.1 and 1.25 points.
Beyond blood sugar, these medications produce meaningful weight loss, which is a major advantage since most people with type 2 diabetes are also trying to lose weight. Semaglutide has also demonstrated cardiovascular protection, reducing the risk of major heart events like heart attack and stroke. This makes GLP-1 agonists a strong second medication (or even a first-line alternative) for people with established heart disease or those who need significant weight reduction.
The tradeoff is side effects. Up to 50% of people taking a GLP-1 agonist experience nausea, especially in the first weeks. Diarrhea is also very common, affecting at least 1 in 10 users. Vomiting, constipation, and abdominal pain occur less frequently. Most people find these symptoms manageable and they tend to fade as the body adjusts, but they’re a real barrier for some. Cost is another consideration: brand-name GLP-1 agonists are significantly more expensive than metformin, and insurance coverage varies widely.
SGLT2 Inhibitors: Best for Heart and Kidney Protection
SGLT2 inhibitors work through a completely different mechanism. They block a protein in the kidneys that normally reabsorbs sugar back into the blood, causing excess glucose to leave the body through urine. This class includes empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana).
Their A1c-lowering power is moderate, roughly 0.7 to 1.0 percentage points depending on the specific drug and dose. Where they truly stand out is organ protection. SGLT2 inhibitors reduce the risk of hospitalization for heart failure and slow the progression of chronic kidney disease. These benefits hold true across different stages of kidney disease and in people with heart failure regardless of whether they have diabetes at all. That’s a remarkable finding, and it’s why these drugs are now specifically recommended for anyone with type 2 diabetes who also has heart failure or declining kidney function.
Side effects reflect the mechanism. Because extra sugar passes through the urinary tract, genital yeast infections are more common, particularly in women. Urinary tract infections also occur at higher rates. Some people experience increased urination and mild dehydration.
Dual and Triple Agonists: The Newest Options
Tirzepatide (Mounjaro) targets two gut hormones instead of one, combining GLP-1 activity with another hormone pathway. It produces greater weight loss than semaglutide alone. However, a real-world study found that semaglutide was associated with a 29% lower risk of major cardiovascular events compared to tirzepatide, suggesting that more weight loss doesn’t automatically translate to better heart protection. Both drugs are actively being studied, and the picture may evolve.
Further out, a triple-hormone agonist called retatrutide is in clinical trials. In a phase 2 study of 281 people with type 2 diabetes, doses between 4 mg and 12 mg lowered A1c by 1.3 to 2.0 percentage points over 36 weeks. The highest doses outperformed dulaglutide, which achieved a 1.4-point reduction in the same trial. Its side effect profile so far looks similar to existing GLP-1 drugs. It is not yet approved for use.
How Other Medication Classes Compare
Several older drug classes remain in use, though they’ve been largely overtaken by the options above:
- Sulfonylureas (glipizide, glimepiride, glyburide) stimulate the pancreas to release more insulin regardless of blood sugar levels. They lower A1c by about 0.9 to 1.2 points and are inexpensive, but they carry a real risk of low blood sugar episodes and tend to cause weight gain.
- DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin) work on a similar hormonal pathway as GLP-1 agonists but are much weaker, lowering A1c by only 0.6 to 0.7 points. They’re well tolerated and weight-neutral, which makes them useful when other options aren’t suitable, but they don’t offer the cardiovascular or kidney benefits of newer drugs.
Choosing Based on Your Health Profile
The decision tree for type 2 diabetes medication has shifted from “what lowers blood sugar the most” to “what else does this person need.” Nearly everyone starts with metformin. After that, the choice of a second medication depends on your other health conditions and priorities.
If you have heart disease or are at high risk for heart attack and stroke, a GLP-1 agonist with proven cardiovascular benefit (like semaglutide) is typically the preferred addition. If you have heart failure or chronic kidney disease, an SGLT2 inhibitor offers targeted protection for those organs. If weight loss is a primary goal and you don’t have specific heart or kidney concerns, a GLP-1 agonist or tirzepatide provides the most significant effect. If cost is the driving factor and you need a second medication beyond metformin, a sulfonylurea remains the cheapest option, though it comes with trade-offs in weight and low blood sugar risk.
Many people with type 2 diabetes eventually take two or three medications together. Metformin paired with an SGLT2 inhibitor and a GLP-1 agonist, for instance, addresses blood sugar from three different angles while providing heart, kidney, and weight benefits simultaneously. The combination that works best is the one matched to your body, your other conditions, and what you can realistically afford and tolerate.